EUVIMEDEUVIMED entdecken
Crossref

Peptide‐Drug Conjugate with Statistically Designed Transcellular Peptide for Psoriasis‐Like Inflammation

Do Hyun Bae, Hayeon Bae, Hyung-Seok Yu, Banzragch Dorjsembe, Young Hyun No, Taejung Kim, Nam Hyeong Kim, Jin-Woo Kim, Jiyool Kim, Bok-Soo Lee, Ye Ji Kim, Seongchan Park und 7 weitere

Advanced Healthcare Materials · 2024-06 · 13 (15)

DOI: 10.1002/adhm.202303480 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 09.03.2024. Verfasst von Do Hyun Bae und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Sungkyunkwan University (SKKU), Suwon, 16419, Republic of Korea. Hauptthemen laut MEDLINE: Psoriasis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Korea Institute of Science and Technology, Korea government (MSIT), Institute for Basic Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peptide‐drug conjugates (PDCs) are a promising class of drug delivery systems that utilize covalently conjugated carrier peptides with therapeutic agents. PDCs offer several advantages over traditional drug delivery systems including enhanced target engagement, improved bioavailability, and increased cell permeability. However, the development of efficient transcellular peptides capable of effectively transporting drugs across biological barriers remains an unmet need. In this study, physicochemical criteria based on cell‐penetrating peptides are employed to design transcellular peptides derived from an antimicrobial peptides library. Among the statistically designed transcellular peptides (SDTs), SDT7 exhibits higher skin permeability, faster kinetics, and improved cell permeability in human keratinocyte cells compared to the control peptide. Subsequently, it is found that 6‐Paradol (PAR) exhibits inhibitory activity against phosphodiesterase 4, which can be utilized for an anti‐inflammatory PDC. The transcellular PDC (SDT7‐conjugated with PAR, named TM5) is evaluated in mouse models of psoriasis, exhibiting superior therapeutic efficacy compared to PAR alone. These findings highlight the potential of transcellular PDCs (TDCs) as a promising approach for the treatment of inflammatory skin disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisAnimalsHumansMiceKeratinocytesInflammationSkinDrug Delivery SystemsCell-Penetrating PeptidesPhosphodiesterase 4 Inhibitors

Stichwörter der Autor:innen

anti‐inflammationginger‐driven compoundspeptide‐drug conjugatesskin barriertranscellular peptide

Substanzen

Cell-Penetrating PeptidesPhosphodiesterase 4 Inhibitors

Autor:innen und Institutionen

  • Department of Biomedical Engineering, Sungkyunkwan University (SKKU), Suwon, 16419, Republic of Korea.
  • Center for Neuroscience Imaging Research (CNIR), Institute for Basic Science (IBS), Suwon, 16419, Republic of Korea.
  • SKKU Advanced Institute of Nano Technology (SAINT), Sungkyunkwan University (SKKU), Suwon, 16419, Republic of Korea.
  • Department of Nano Science and Technology, Sungkyunkwan University (SKKU), Suwon, 16419, Republic of Korea.
  • Natural Products Research Institute, Korea Institute of Science and Technology (KIST), Gangneung, 25451, Republic of Korea.
  • Division of Bio-Medical Science & Technology, University of Science and Technology (UST), Daejeon, 34113, Republic of Korea.

ORCID-Profile: Yong Ho Kim

Förderung

  • Korea Institute of Science and Technology
  • Korea government (MSIT)
  • Institute for Basic Science
  • Nano Convergence Industrial Strategic Technology Development program
  • IMNEWRUN CORPORATION

Zitieren

APA

Bae, D. H., Bae, H., Yu, H. S., Dorjsembe, B., No, Y. H., Kim, T., Kim, N. H., Kim, J. W., Kim, J., Lee, B. S., Kim, Y. J., Park, S., Khaleel, Z. H., Sa, D. H., Lee, E. C., Lee, J., Ham, J., Kim, J. C., & Kim, Y. H. (2024). Peptide‐Drug Conjugate with Statistically Designed Transcellular Peptide for Psoriasis‐Like Inflammation. Advanced Healthcare Materials, 13(15). https://doi.org/10.1002/adhm.202303480

Vancouver

Bae DH, Bae H, Yu HS, Dorjsembe B, No YH, Kim T, et al. Peptide‐Drug Conjugate with Statistically Designed Transcellular Peptide for Psoriasis‐Like Inflammation. Advanced Healthcare Materials. 2024;13(15). doi:10.1002/adhm.202303480

BibTeX
@article{Bae2024,
  author = {Bae, Do Hyun and Bae, Hayeon and Yu, Hyung-Seok and Dorjsembe, Banzragch and No, Young Hyun and Kim, Taejung and Kim, Nam Hyeong and Kim, Jin-Woo and Kim, Jiyool and Lee, Bok-Soo and Kim, Ye Ji and Park, Seongchan and Khaleel, Zinah Hilal and Sa, Deok Hyang and Lee, Eui-Chul and Lee, Jaecheol and Ham, Jungyeob and Kim, Jin-Chul and Kim, Yong Ho},
  title = {Peptide‐Drug Conjugate with Statistically Designed Transcellular Peptide for Psoriasis‐Like Inflammation},
  journal = {Advanced Healthcare Materials},
  year = {2024},
  volume = {13},
  number = {15},
  doi = {10.1002/adhm.202303480}
}
Kostenlos starten →